HCLS1 binding protein 3Genealiases: ETM2 · HS1-BP3
Q-omics provides the consensus-scored HS1BP3 profile across patient tissues and cancer cell-line models. HS1BP3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HS1BP3 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, HS1BP3 protein abundance shows 22,748 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where HS1BP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HS1BP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HS1BP3 survival associations across molecular data types. HS1BP3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HS1BP3 RNA expression–survival associations across cancer types. High HS1BP3 expression shows unfavorable associations in UVM, BLCA, LIHC, ACC and UCS, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HS1BP3 RNA expression.
This table summarizes HS1BP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for HS1BP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HS1BP3 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, KIRC, LIHC and KIRP. The HNSC box plot shows higher HS1BP3 RNA expression in tumor versus normal tissue (log2 FC = +1.177, t-test p < 0.001).
This table shows molecular features associated with HS1BP3 in patient tissues and cancer cell lines. In patient samples, HS1BP3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HS1BP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LIVER and SKIN.
